Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Myc down-regulation induces apoptosis in M14 melanoma cells by increasing p27kip1 levels

Abstract

In recent years, increasing evidence indicated the importance of a deregulated c-myc gene in the melanoma pathogenesis. We have previously demonstrated that treatment of melanoma cells with c-myc antisense oligodeoxynucleotides can inhibit cell proliferation and activate apoptosis. To gain insight into the mechanisms activated by Myc down-regulation, we have now developed an experimental model that allows modulating Myc protein expression in melanoma cells. This was achieved by originating stable melanoma cell clones expressing ecdysone-inducible c-myc antisense RNA. We show that the induction of c-myc antisense RNA in M14 melanoma cells leads to an inhibition of cell proliferation characterized by accumulation of cells in the G1 phase of the cell cycle (up to 80%) and activation of apoptosis (50%). These data are associated with an increase of p27kip1 levels and a significant reduction of the cdk2-associated kinase activity. In addition, we show that an ectopic overexpression of p27kip1 in this experimental model can enhance the apoptotic rate. Our results indicate that down-regulation of Myc protein induces a G1 arrest and activates apoptosis by increasing p27kip1 content in melanoma cells, that are known to be defective for the p16-cyclinD/cdk4-pRb G1 checkpoint. This is particularly relevant for identifying new therapeutic strategies based on the re-establishment of the apoptotic pathways in cancer cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J . 1996 Cancer Res. 56: 5475–5483

  • Burgess TL, Fisher EF, Ross SL, Bready JV, Qian YX, Bayewitch LA, Cohen AM, Herrera CJ, Hu SS, Kramer TB . 1995 Proc. Natl. Acad. Sci. USA 92: 4051–4055

  • Castellano M, Parmiani G . 1999 Melanoma Res. 9: 421–432

  • Citro G, D'Agnano I, Leonetti C, Perini R, Bucci B, Zon G, Calabretta B, Zupi G . 1998 Cancer Res. 58: 283–289

  • Crooke ST . 1996 Antisense Nucleic Acid Drug Dev. 6: 145–147

  • D'Agnano I, Antonelli A, Bucci B, Marcucci L, Petrinelli P, Ambra R, Zupi G, Elli R . 1998 Environ. Mol. Mutagen. 32: 56–63

  • Daksis JI, Lu RY, Facchini LM, Marhin WW, Penn LJ . 1994 Oncogene 9: 3635–3645

  • Dang CV . 1999 Mol. Cell Biol. 19: 1–11

  • Evan G, Littlewood T . 1998 Science 281: 1317–1322

  • Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC . 1992 Cell 69: 119–128

  • Ezhevsky SA, Toyoshima H, Hunter T, Scott DW . 1996 Mol. Biol. Cell 7: 553–564

  • Fischer G, Kent SC, Joseph L, Green DR, Scott DW . 1994 J. Exp. Med. 179: 221–228

  • Hanson KD, Shichiri M, Follansbee MR, Sedivy JM . 1994 Mol. Cell Biol. 14: 5748–5755

  • Hoang AT, Cohen KJ, Barrett JF, Bergstrom DA, Dang CV . 1994 Proc. Natl. Acad. Sci. USA 91: 6875–6879

  • Jansen-Durr P, Meichle A, Steiner P, Pagano M, Finke K, Botz J, Wessbecher J, Draetta G, Eilers M . 1993 Proc. Natl. Acad. Sci. USA 90: 3685–3689

  • Kalejta RF, Shenk T, Beavis AJ . 1997 Cytometry 29: 286–291

  • Katayose Y, Kim M, Rakkar AN, Li Z, Cowan KH, Seth P . 1997 Cancer Res. 57: 5441–5445

  • Kimura S, Maekawa T, Hirakawa K, Murakami A, Abe T . 1995 Cancer Res. 55: 1379–1384

  • Krieg AM, Stein CA . 1995 Antisense Res. Dev. 5: 241

  • Leone G, DeGregori J, Sears R, Jakoi L, Nevins JR . 1997 Nature 387: 422–426

  • Leonetti C, D'Agnano I, Lozupone F, Valentini A, Geiser T, Zon G, Calabretta B, Citro GC, Zupi G . 1996 J. Natl. Cancer Inst. 88: 419–429

  • Lesnikowski ZJ, Jaworska M, Stec WJ . 1990 Nucleic Acids Res. 18: 2109–2115

  • Maelandsmo GM, Florenes VA, Hovig E, Oyjord T, Engebraaten O, Holm R, Borresen AL, Fodstad O . 1996 Br. J. Cancer 73: 909–916

  • Mateyak MK, Obaya AJ, Sedivy JM . 1999 Mol. Cell Biol. 19: 4672–4683

  • O'Hagan RC, Ohh M, David G, de Alboran IM, Alt FW, Kaelin Jr WG, DePinho RA . 2000 Genes Dev. 14: 2185–2191

  • Obaya AJ, Mateyak MK, Sedivy JM . 1999 Oncogene 18: 2934–2941

  • Perez-Roger I, Solomon DL, Sewing A, Land H . 1997 Oncogene 14: 2373–2381

  • Ross DA, Wilson GD . 1998 Br. J. Surg. 85: 46–51

  • Ryan KM, Birnie GD . 1996 Biochem. J. 314: 713–721

  • Schlagbauer-Wadl H, Griffioen M, van Elsas A, Schrier PI, Pustelnik T, Eichler HG, Wolff K, Pehamberger H, Jansen B . 1999 J. Invest. Dermatol. 112: 332–336

  • Schmidt EV . 1999 Oncogene 18: 2988–2996

  • Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP, Sauter G . 1999 Clin. Cancer Res. 5: 1966–1975

  • Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE . 1997 Genes Dev. 11: 1464–1478

  • Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP, Green DR . 1992 Science 257: 212–214

  • Skorski T, Nieborowska-Skorska M, Campbell K, Iozzo RV, Zon G, Darzynkiewicz Z, Calabretta B . 1995 J. Exp. Med. 182: 1645–1653

  • Stein CA . 1996 J. Natl. Cancer Inst. 88: 391–393

  • Stein CA . 1998 Antisense Nucleic Acid Drug Dev. 8: 129–132

  • Van den Heuvel S, Harlow E . 1993 Science 262: 2050–2054

  • van Waardenburg RC, Meijer C, Burger H, Nooter K, de Vries EG, Mulder NH, De Jong S . 1997 Int. J. Cancer 73: 544–550

  • Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B . 1996 EMBO J. 15: 6595–6604

  • Vlach J, Hennecke S, Amati B . 1997 EMBO J. 16: 5334–5344

  • Wang X, Gorospe M, Huang Y, Holbrook NJ . 1997 Oncogene 15: 2991–2997

  • Wu M, Bellas RE, Shen J, Yang W, Sonenshein GE . 1999 J. Immunol. 163: 6530–6535

Download references

Acknowledgements

We thank Maurizia Caruso for critically reading the manuscript; and Alessandra Rinaldi for technical assistance. This work was supported by grants from CNR, Target Project on Biotechnology (to I D'Agnano) and Progetto Strategico ‘Oncologia’ MURST-CNR (to A Felsani).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

D'Agnano, I., Valentini, A., Fornari, C. et al. Myc down-regulation induces apoptosis in M14 melanoma cells by increasing p27kip1 levels. Oncogene 20, 2814–2825 (2001). https://doi.org/10.1038/sj.onc.1204392

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204392

Keywords

This article is cited by

Search

Quick links